Abbott said it is facing pricing pressure and slower growth ahead of a planned coverage expansion for people with Type 2 diabetes. Competitor Dexcom, however, did not experience the same slowdown.
Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion